Press Release Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer 11 hours ago
Press Release Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer Aug 13
Press Release Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results Jul 28